Sign up


Match Document Document Title
6106822 Hormone and growth factor phosphoglycokine mimetics from mycobacterium  
A hormone or growth factor mimetic second messenger is derived from a microorganism of the genus Mycobacterium, suitably M. vaccae. The mimetic second messenger may mimic the action of insulin,...
6103224 N∇2 CSF-1 (short form) and carboxy truncated fragments thereof  
A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from...
6099846 Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates  
B cell lymphoma tumor-associated antigen or a fragment thereof containing an epitope are linked to an immune-enhancing cytokine, such as GM-CSF, IL-2, or IL-4 to form an immuno-complex. This...
6096300 Treatment of myeloproliferative disease with exodus chemokine  
The present invention provides purified and isolated chemokine protein, fragments and polypeptide analogs thereof, antibodies thereto, and materials and methods for the recombinant production...
6096320 Vaccines with chimeric protein comprising gamma-interferon and leukotoxin derived from pasteurella haemolytica  
New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are...
6093381 Modulation of the sensitivity of tumor cells to chemotherapeutics  
Disclosed is a method for improving the treatment of a cancer patient which is undergoing (adjuvant) chemotherapy. Prior to or concomitant with the patient receiving adjuvant chemotherapy, the...
6093699 Method for gene therapy involving suppression of an immune response  
A method for specifically suppressing the capacity of a mammal receiving gene therapy to mount an immune response to a given expressed gene of the deficient gene in question, which response is...
6093390 Methods for promoting functional regeneration of mammalian muscle by administering leukaemia inhibitor factor  
The present invention relates to a method for regulating neuron development, maintenance and regeneration in the central and peripheral nervous systems of a mammal and to pharmaceutical...
6093405 Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines  
Cytokines, which are biologically inactive in humans but remain immunogenic, are used in pharmaceutical compositions to promote a neutralizing immune response against native cytokines when...
6093391 Peptide copolymer compositions  
Compositions of peptides and block copolymers and methods of treatment using the same. The compositions enhance the activity of peptide-based and related biological agents, and reduce adverse side...
6090377 Monocyte activating cytokine  
The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells...
6090918 Receptor protein designated 2F1  
2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting...
6086866 Use of platelet-derived growth factor to improve collateral circulation  
The present invention provides a non-invasive method for improving collateral circulation to tissue at risk of ischemia or ischemic necrosis. Improved collateral circulation is obtained by applying...
6086868 Method for treating or preventing ischemia-reperfusion injury  
There is disclosed a method of treating ischemia-reperfusion injury comprising administering an effective amount of Interleukin-10 to a patient suffering or expected to suffer from such injury.
6086867 Modulation of TGF-β by TGF-β type III receptor polypeptides  
DNA encoding TGF-β TYPE III receptor of mammalian origin, DNA encoding TGF-β type II receptor of mammalian origin, TGF-β type III receptor. TGF-β type II receptor and uses therefor.
6086865 Methods of treating angiogenesis-induced diseases and pharmaceutical compositions thereof  
The present invention provides for the use of fumagillin or an O-substituted fumagillol derivative in conjunction with interferon which increases the angiogenic inhibitory action as compared with...
6083907 Treatment of peptic ulcers using midkine (MK) proteins  
An anti-ulcer composition is provided, which comprises as an active ingredient at least one of MK protein, its derivative having biological activity of MK protein, and their fragment having...
6084071 Human L105 polypeptides and polynucleotides encoding same  
A chemokine, human L105, is disclosed.
6083534 Pharmaceutical compositions for controlled release of soluble receptors  
A controlled release pharmaceutical composition includes a biocompatible polymeric material, preferably polyethylene-vinyl acetate or poly(lactic-glucolic acid), having incorporated therein a...
6083906 Method of regulating nitric oxide production or arthritis with soluble IL-17 receptor  
Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.
6083503 Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection  
A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T...
RE36755 DNA encoding tumor necrosis factor-α and -β receptors  
Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
6080398 Truncated gro and KC chemokines having enhanced bioactivity  
The present invention provides method of increasing the biological activity of KC, gro-α, gro-β, and gro-γ proteins, truncated and modified proteins characterized by having biological activity at...
6077519 Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients  
Methods are provided for eluting peptides that are bound to major histocompatibility complex ("MHC") molecules expressed on the cell surfaces of viable cells that have at least one MHC-peptide...
6074635 T cell activation  
Methods for activating T cells in the absence of antigen, and compositions for effecting the same, are described.
6074639 Ex vivo expansion of hematopoietic cells using interleukin-3 (IL-3) variant fusion proteins  
The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF),...
6066318 Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors  
Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional...
6063372 Uses of mammalian CTLA-8 and related reagents  
Compositions and methods for using CTLA-8 to treat an abnormal physiological condition in an individual. The methods comprise administering a therapeutically effective amount of CTLA-8 alone, or in...
6063757 Wound treatment method with nerve growth factor  
A method is provided for healing chronic wounds in a subject, particularly wounds which exhibit poor vascularization and sensory loss. The treatment method involves administering a therapeutically...
6063373 Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor  
An improved method for the prevention of the inactivation of natural killer (NK) cells and the enhanced activation of NK cells in the presence of monocytes using a combination of a natural killer...
6057133 Multivariant human IL-3 fusion proteins and their recombinant production  
The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF),...
6048971 Recombinant human erythropoietin mutants  
DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant...
6048837 OB polypeptides as modulators of body weight  
The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and...
6042826 Method for inducing apoptosis of primary central nervous system B cell lymphomas  
A method for treating a primary central nervous system lymphoma in an individual relates to administering intrathecally or intralesionally a therapeutically effective amount of a Fas-cross-linking...
6043344 Human CTLA-8 and uses of CTLA-8-related proteins  
Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8...
6042821 Method of treating sepsis with chemokines  
The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC [SEQ ID NO: 1], groα [SEQ ID NO:2], groβ [SEQ ID NO: 3] or groγ [SEQ ID NO...
6030812 Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors  
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins,...
6028050 Method for increasing platelets by administering soluble interleukin-6 receptor  
A platelet-increasing preparation which comprises an effective amount of an interleukin-6 receptor and a pharmaceutically acceptable excipient. Preferably the preparation further comprises...
6027720 G-CSF conjugate  
Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least...
6025325 Pegylated obese (ob) protein compositions  
Polyethylene and polypropylene protein conjugates which modulate body weight of animals and humans for the treatment, prevention and control of obesity and associated diseases or conditions, and...
6025324 Pegylated obese (ob) protein compositions  
Polyethylene and polypropylene protein conjugates which modulate body weight of ani is and humans for the treatment, prevention and control obesity and associated diseases or conditions, and the...
6022535 Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors  
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins,...
6020323 Compositions and methods for regulation of active TNF-α  
Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the...
6019965 Methods for treatment of pulmonary disease using GM-CSF  
Methods of treatment of pulmonary disease, e.g., alveolar proteinosis, by treating a subject with an effective amount of GM-CSF.
6017544 Composition comprising immunogenic stress protein-peptide complexes against cancer and a cytokine  
Disclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed...
6017540 Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6017876 Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity  
The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific...
6015883 Rantes homolog from prostate  
The present invention provides a polynucleotide (PTEC) isolated from a prostate cDNA library which identifies and encodes a novel human rantes homolog PTEC (prostate expressed chemokine). The...
6015552 Use of nerve growth factor-2 (NGF-2) /neurotrophin-3 (NT-3) to promote leukocyte proliferation  
Human Nerve Growth Factor-2 (NGF-2, also known as Neurotrophin-3 or NT-3) has been found to promote the proliferation of peripheral blood leukocytes. The invention provides methods using hNGF-2...
6013252 Method promoting conception by administering IL-8 or MCAF  
Leukocyte chemotactic factors such as interleukin-8 and MCAF, and inductive substances therefor were revealed to have proconceptive activities. These activities include promoting ovum growth and...